Beyond immune checkpoint blockade: emerging immunological strategies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond immune checkpoint blockade: emerging immunological strategies
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-08
DOI
10.1038/s41573-021-00155-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer
- (2020) D. Planchard et al. ANNALS OF ONCOLOGY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
- (2020) Marcus Ruscetti et al. CELL
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Choline acetyltransferase–expressing T cells are required to control chronic viral infection
- (2019) Maureen A. Cox et al. SCIENCE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
- (2019) M D Hellmann et al. ANNALS OF ONCOLOGY
- LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
- (2019) T K Owonikoko et al. ANNALS OF ONCOLOGY
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Lisa F. Licitra et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- TOX is a critical regulator of tumour-specific T cell differentiation
- (2019) Andrew C. Scott et al. NATURE
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
- (2019) Rohit R. Jadhav et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fcmr regulates mononuclear phagocyte control of anti-tumor immunity
- (2019) Shawn P. Kubli et al. Nature Communications
- 1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
- (2019) A Marabelle et al. ANNALS OF ONCOLOGY
- LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
- (2019) A M Arance et al. ANNALS OF ONCOLOGY
- 1874OInterferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
- (2019) J Luke et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade
- (2019) Haoxin Li et al. Nature Communications
- The Role of Tumor Microenvironment in Genomic Instability of Malignant Tumors
- (2019) F. Gizem Sonugür et al. Frontiers in Genetics
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors
- (2018) Jiemiao Hu et al. CLINICAL CANCER RESEARCH
- Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
- (2018) Pedro Berraondo et al. CLINICAL CANCER RESEARCH
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Human dendritic cell subsets: an update
- (2018) Matthew Collin et al. IMMUNOLOGY
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
- (2018) Tuo Li et al. JOURNAL OF EXPERIMENTAL MEDICINE
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma
- (2018) Sandra P. D'Angelo et al. Cancer Discovery
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
- (2018) Nehal J. Lakhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes
- (2018) Oscar M. Leung et al. Cell Reports
- 1378OARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
- (2018) D M Kowalski et al. ANNALS OF ONCOLOGY
- 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
- (2018) P A Ascierto et al. ANNALS OF ONCOLOGY
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
- (2018) Matthew M. Gubin et al. CELL
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Trends in the global immuno-oncology landscape
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mouse Models for Cancer Immunotherapy Research
- (2018) Brian Olson et al. Cancer Discovery
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
- (2017) Hanke L. Matlung et al. IMMUNOLOGICAL REVIEWS
- M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases
- (2017) Katyayni Vinnakota et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2017) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
- (2017) Robert Sackstein et al. LABORATORY INVESTIGATION
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- The benefits of immunotherapy combinations
- (2017) Charles Schmidt NATURE
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- A distinct innate lymphoid cell population regulates tumor-associated T cells
- (2017) Sarah Q Crome et al. NATURE MEDICINE
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Exhaustion-associated regulatory regions in CD8+tumor-infiltrating T cells
- (2017) Giuliana P. Mognol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens
- (2017) Takuji Hayashi et al. PROSTATE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
- (2017) Kenji Gonda et al. Oncology Letters
- Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells
- (2017) M. Fehlings et al. Nature Communications
- Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis
- (2017) Devy Deliyanti et al. Nature Communications
- Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
- (2017) Martin Lauss et al. Nature Communications
- Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis
- (2017) Jian Cao et al. Oncotarget
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- The Multifaceted Role of Perivascular Macrophages in Tumors
- (2016) Claire E. Lewis et al. CANCER CELL
- A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency
- (2016) Simone Punt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8 + T Cells
- (2016) Deepak Mittal et al. CANCER RESEARCH
- Mechanism involved in interleukin-21-induced phagocytosis in human monocytes and macrophages
- (2016) F. Vallières et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells
- (2016) Daniel S. Leventhal et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Blood pressure regulation by CD4+ lymphocytes expressing choline acetyltransferase
- (2016) Peder S Olofsson et al. NATURE BIOTECHNOLOGY
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- IL-21 and T Cell Differentiation: Consider the Context
- (2016) Yuan Tian et al. TRENDS IN IMMUNOLOGY
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy
- (2016) Sangeetha M. Reddy et al. Current Oncology Reports
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
- (2016) Lewis Zhichang Shi et al. Nature Communications
- Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity
- (2016) Yang-Zhuo Gu et al. Scientific Reports
- Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3
- (2016) Dror Alishekevitz et al. Cell Reports
- Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
- (2016) Anna-Maria Georgoudaki et al. Cell Reports
- Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors
- (2016) Alexander K. Tsai et al. OncoImmunology
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody
- (2015) L. Xue et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Failures in Phase III: Causes and Consequences
- (2015) B. Seruga et al. CLINICAL CANCER RESEARCH
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Targeting the tumor vasculature to enhance T cell activity
- (2015) Evripidis Lanitis et al. CURRENT OPINION IN IMMUNOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis
- (2015) Huan Tao et al. JOURNAL OF LIPID RESEARCH
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
- (2015) Nicholas Butowski et al. NEURO-ONCOLOGY
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- IL-21-mediated non-canonical pathway for IL-1β production in conventional dendritic cells
- (2015) Chi-Keung Wan et al. Nature Communications
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trafficking of T Cells into Tumors
- (2014) C. Y. Slaney et al. CANCER RESEARCH
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- The origin and function of tumor-associated macrophages
- (2014) Yang Liu et al. Cellular & Molecular Immunology
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- The CD47-SIRP signalling system: its physiological roles and therapeutic application
- (2014) Y. Murata et al. JOURNAL OF BIOCHEMISTRY
- Apoptotic Cells Protect Mice against Lipopolysaccharide-Induced Shock
- (2014) Y. Ren et al. JOURNAL OF IMMUNOLOGY
- Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2014) J.-I. Youn et al. JOURNAL OF IMMUNOLOGY
- Endothelin receptor antagonists in clinical research — Lessons learned from preclinical and clinical kidney studies
- (2014) Christoph Reichetzeder et al. LIFE SCIENCES
- The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells
- (2014) Frédérique Végran et al. NATURE IMMUNOLOGY
- The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells
- (2014) Makoto Kurachi et al. NATURE IMMUNOLOGY
- The cellular and molecular origin of tumor-associated macrophages
- (2014) R. A. Franklin et al. SCIENCE
- Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
- (2014) Andrew J.S. Furness et al. TRENDS IN IMMUNOLOGY
- Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
- (2014) Damya Laoui et al. Frontiers in Immunology
- Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment
- (2014) Gregory L Beatty et al. OncoImmunology
- Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
- (2014) Theerawut Chanmee et al. Cancers
- The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
- (2013) A. Neil Barclay et al. Annual Review of Immunology
- Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
- (2013) Angelique W. Whitehurst Annual Review of Pharmacology and Toxicology
- Macrophage Regulation of Tumor Responses to Anticancer Therapies
- (2013) Michele De Palma et al. CANCER CELL
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Clearance of Apoptotic Cells by Macrophages Induces Regulatory Phenotype and Involves Stimulation of CD36 and Platelet-Activating Factor Receptor
- (2013) Matheus Ferracini et al. MEDIATORS OF INFLAMMATION
- Macrophage biology in development, homeostasis and disease
- (2013) Thomas A. Wynn et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages are required for adult salamander limb regeneration
- (2013) James W. Godwin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
- (2013) Zachary A. Cooper et al. OncoImmunology
- Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
- (2013) Matteo Bellone et al. Frontiers in Oncology
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion
- (2012) J. P. Hindley et al. CANCER RESEARCH
- The Next Challenge in Cancer Immunotherapy: Controlling T-Cell Traffic to the Tumor
- (2012) J.-P. Abastado CANCER RESEARCH
- Exploiting the Mutanome for Tumor Vaccination
- (2012) J. C. Castle et al. CANCER RESEARCH
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- NF- B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells
- (2012) R. Muthuswamy et al. CANCER RESEARCH
- Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
- (2012) A. M. Mulligan et al. CLINICAL CANCER RESEARCH
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Metabolic checkpoints in activated T cells
- (2012) Ruoning Wang et al. NATURE IMMUNOLOGY
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
- (2012) A. Schietinger et al. SCIENCE
- Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
- (2012) M. A. Paley et al. SCIENCE
- Protective Roles of Natural IgM Antibodies
- (2012) Caroline Grönwall et al. Frontiers in Immunology
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
- (2011) M. Hong et al. CANCER RESEARCH
- IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology
- (2011) Marc Pellegrini et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
- (2011) Sid P. Kerkar et al. JOURNAL OF CLINICAL INVESTIGATION
- Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions
- (2011) Alessandra Nardin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
- (2010) C. Sportes et al. CLINICAL CANCER RESEARCH
- Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses
- (2010) W. Peng et al. CLINICAL CANCER RESEARCH
- Tumors as Organs: Complex Tissues that Interface with the Entire Organism
- (2010) Mikala Egeblad et al. DEVELOPMENTAL CELL
- Intratumoral Interleukin-21 Increases Antitumor Immunity, Tumor-infiltrating CD8+ T-cell Density and Activity, and Enlarges Draining Lymph Nodes
- (2010) Henrik Søndergaard et al. JOURNAL OF IMMUNOTHERAPY
- Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma
- (2010) Yoichi Ohtaki et al. Journal of Thoracic Oncology
- Genomic instability — an evolving hallmark of cancer
- (2010) Simona Negrini et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fighting cancers from within: augmenting tumor immunity with cytokine therapy
- (2010) Marc Pellegrini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Endothelin B Receptor, a New Target in Cancer Immune Therapy
- (2009) L. E. Kandalaft et al. CLINICAL CANCER RESEARCH
- The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
- (2009) A. H. Beck et al. CLINICAL CANCER RESEARCH
- Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies
- (2009) Marc Pellegrini et al. NATURE MEDICINE
- A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth
- (2009) Binzhi Qian et al. PLoS One
- IL-21 Is Required to Control Chronic Viral Infection
- (2009) H. Elsaesser et al. SCIENCE
- Targeting metastatic melanoma
- (2008) J. Poust AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit
- (2008) Kotaro Sasaki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
- (2008) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The scavenger receptor SR-A I/II (CD204) signals via the receptor tyrosine kinase Mertk during apoptotic cell uptake by murine macrophages
- (2008) Jill C. Todt et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Haematopoietic stem cell release is regulated by circadian oscillations
- (2008) Simón Méndez-Ferrer et al. NATURE
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started